Skip to main content
Clinical Trials/ACTRN12618000566235
ACTRN12618000566235
Active, not recruiting
Phase 2

Ablative Stereotactic Radiotherapy as an alternative to systemic treatment in men with oligometastatic prostate cancer and controlled primary disease. A prospective Phase II study measuring toxicity, disease control and freedom from escalation in systemic therapy

Integrated Clinical Oncology Network Pty Ltd (ICON)0 sites208 target enrollmentApril 13, 2018

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Integrated Clinical Oncology Network Pty Ltd (ICON)
Enrollment
208
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 13, 2018
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Integrated Clinical Oncology Network Pty Ltd (ICON)

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed diagnosis of prostate cancer.
  • \- Biochemical relapses of prostate cancer following radical local treatment.
  • \- Males aged 18 years to 80 years inclusive.
  • \- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\.
  • \- N1 and M1 a/b disease on imaging, with a combined maximum of five synchronous lesions
  • \- Exclusion of local relapse.
  • \- Metastases suitable for ablative radiotherapy

Exclusion Criteria

  • \- No prior palliative radiotherapy (definitive radiotherapy as part of initial management is allowed).
  • \- Active local disease on clinical examination.

Outcomes

Primary Outcomes

Not specified

Similar Trials